Want to see HRMY full AI Analyst Report?
Harmony Biosciences Holdings (HRMY) Ratios
Harmony Biosciences Holdings Ratios
HRMY's free cash flow for Q2 2026 was $92.43M. For the 2026 fiscal year, HRMY's free cash flow was increased by $0.00 and operating cash flow was $92.43M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.60 | 3.31 | 2.75 | 5.07 | 5.29 |
| Quick Ratio | 3.58 | 3.27 | 2.72 | 5.02 | 5.21 |
| Cash Ratio | 2.98 | 2.59 | 1.90 | 3.09 | 4.36 |
| Solvency Ratio | 0.46 | 0.50 | 0.44 | 0.76 | 0.22 |
| Operating Cash Flow Ratio | 1.38 | 1.26 | 1.34 | 1.83 | 1.83 |
| Short-Term Operating Cash Flow Coverage | 4.01 | 13.53 | 14.63 | 72.23 | 49.28 |
| Net Current Asset Value | $ 505.60M | $ 239.21M | $ 106.61M | $ 129.25M | $ 37.50M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.19 | 0.18 | 0.24 | 0.28 | 0.45 |
| Debt-to-Equity Ratio | 0.28 | 0.28 | 0.41 | 0.48 | 1.05 |
| Debt-to-Capital Ratio | 0.22 | 0.22 | 0.29 | 0.32 | 0.51 |
| Long-Term Debt-to-Capital Ratio | 0.15 | 0.20 | 0.28 | 0.32 | 0.50 |
| Financial Leverage Ratio | 1.46 | 1.52 | 1.74 | 1.67 | 2.32 |
| Debt Service Coverage Ratio | 1.96 | 5.54 | 4.57 | 10.75 | 2.96 |
| Interest Coverage Ratio | 14.23 | 10.91 | 8.08 | 6.39 | 3.62 |
| Debt to Market Cap | 0.11 | 0.09 | 0.10 | 0.06 | 0.08 |
| Interest Debt Per Share | 4.42 | 3.50 | 3.65 | 3.56 | 3.82 |
| Net Debt to EBITDA | -2.01 | -1.16 | -0.53 | -0.35 | -0.48 |
| Profitability Margins | |||||
| Gross Profit Margin | 77.16% | 78.06% | 79.17% | 80.93% | 81.82% |
| EBIT Margin | 26.45% | 29.28% | 33.87% | 28.20% | 20.17% |
| EBITDA Margin | 29.37% | 32.66% | 38.06% | 33.54% | 26.34% |
| Operating Profit Margin | 24.00% | 26.70% | 32.99% | 27.45% | 28.66% |
| Pretax Profit Margin | 24.76% | 26.84% | 29.79% | 23.91% | 12.25% |
| Net Profit Margin | 18.27% | 20.36% | 22.14% | 41.44% | 11.33% |
| Continuous Operations Profit Margin | 18.27% | 20.36% | 22.14% | 41.44% | 11.33% |
| Net Income Per EBT | 73.79% | 75.86% | 74.31% | 173.35% | 92.44% |
| EBT Per EBIT | 103.16% | 100.51% | 90.30% | 87.10% | 42.76% |
| Return on Assets (ROA) | 12.48% | 14.56% | 15.88% | 26.93% | 7.98% |
| Return on Equity (ROE) | 18.24% | 22.07% | 27.59% | 45.05% | 18.55% |
| Return on Capital Employed (ROCE) | 20.45% | 23.16% | 29.65% | 20.20% | 23.05% |
| Return on Invested Capital (ROIC) | 13.90% | 17.20% | 21.53% | 20.13% | 21.12% |
| Return on Tangible Assets | 13.42% | 16.42% | 19.11% | 35.38% | 11.95% |
| Earnings Yield | 7.38% | 7.43% | 6.71% | 5.57% | 1.41% |
| Efficiency Ratios | |||||
| Receivables Turnover | 8.97 | 8.61 | 7.85 | 8.00 | 8.77 |
| Payables Turnover | 11.21 | 11.41 | 6.84 | 22.05 | 55.46 |
| Inventory Turnover | 37.02 | 21.79 | 22.61 | 19.43 | 12.53 |
| Fixed Asset Turnover | 162.51 | 211.52 | 1568.79 | 764.14 | 74.17 |
| Asset Turnover | 0.68 | 0.72 | 0.72 | 0.65 | 0.70 |
| Working Capital Turnover Ratio | 1.64 | 2.07 | 1.91 | 1.59 | 1.70 |
| Cash Conversion Cycle | 17.98 | 27.17 | 9.26 | 47.87 | 64.19 |
| Days of Sales Outstanding | 40.68 | 42.40 | 46.49 | 45.63 | 41.64 |
| Days of Inventory Outstanding | 9.86 | 16.75 | 16.15 | 18.79 | 29.14 |
| Days of Payables Outstanding | 32.56 | 31.99 | 53.38 | 16.55 | 6.58 |
| Operating Cycle | 50.54 | 59.16 | 62.64 | 64.42 | 70.78 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 6.06 | 3.86 | 3.69 | 2.44 | 1.71 |
| Free Cash Flow Per Share | 6.05 | 3.84 | 3.68 | 2.44 | 1.71 |
| Dividend Paid and CapEx Coverage Ratio | 1123.22 | 190.65 | 703.16 | 839.92 | 330.73 |
| Capital Expenditure Coverage Ratio | 1123.22 | 190.65 | 703.16 | 839.92 | 330.73 |
| Operating Cash Flow Coverage Ratio | 1.45 | 1.21 | 1.13 | 0.75 | 0.50 |
| Operating Cash Flow to Sales Ratio | 0.40 | 0.31 | 0.38 | 0.33 | 0.32 |
| Free Cash Flow Yield | 16.17% | 11.17% | 11.40% | 4.43% | 4.01% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 13.56 | 13.44 | 14.91 | 17.97 | 70.91 |
| Price-to-Sales (P/S) Ratio | 2.48 | 2.74 | 3.30 | 7.45 | 8.03 |
| Price-to-Book (P/B) Ratio | 2.47 | 2.97 | 4.11 | 8.09 | 13.15 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 6.18 | 8.95 | 8.77 | 22.60 | 24.97 |
| Price-to-Operating Cash Flow Ratio | 6.18 | 8.90 | 8.76 | 22.57 | 24.89 |
| Price-to-Earnings Growth (PEG) Ratio | 1.74 | 0.75 | -0.51 | 0.04 | -0.46 |
| Enterprise Value Multiple | 6.42 | 7.22 | 8.14 | 21.85 | 30.01 |
| Enterprise Value | 1.64B | 1.69B | 1.80B | 3.21B | 2.41B |
| EV to EBITDA | 6.42 | 7.22 | 8.14 | 21.85 | 30.01 |
| EV to Sales | 1.89 | 2.36 | 3.10 | 7.33 | 7.91 |
| EV to Free Cash Flow | 4.71 | 7.71 | 8.23 | 22.23 | 24.57 |
| EV to Operating Cash Flow | 4.71 | 7.67 | 8.22 | 22.21 | 24.50 |
| Tangible Book Value Per Share | 13.58 | 9.60 | 5.55 | 4.09 | 0.74 |
| Shareholders’ Equity Per Share | 15.14 | 11.59 | 7.85 | 6.81 | 3.24 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.26 | 0.24 | 0.26 | -0.73 | 0.08 |
| Revenue Per Share | 15.11 | 12.56 | 9.79 | 7.40 | 5.31 |
| Net Income Per Share | 2.76 | 2.56 | 2.17 | 3.07 | 0.60 |
| Tax Burden | 0.74 | 0.76 | 0.74 | 1.73 | 0.92 |
| Interest Burden | 0.94 | 0.92 | 0.88 | 0.85 | 0.61 |
| Research & Development to Revenue | 0.22 | 0.20 | 0.13 | 0.16 | 0.10 |
| SG&A to Revenue | 0.31 | 0.31 | 0.16 | 0.19 | 0.21 |
| Stock-Based Compensation to Revenue | 0.05 | 0.06 | 0.05 | 0.06 | 0.05 |
| Income Quality | 2.19 | 1.51 | 1.70 | 0.80 | 2.85 |
Currency in USD
